As a result of the UK losing membership in the EU, the MHRA will no longer be able to engage in EMA’s centralized regulatory procedures which are expected to finalize after March 2019. Therefore, EMA’s Management Board announced the endorsement of a mandate, articulated at its June 14, 2017 meeting, “to establish a working group which will explore options for a reasonable and robust allocation of the workload related to human medicines across the Network.”
[/membership][membership level=”0,4″][The content continues for paid members only.]
Login or Subscribe [/membership][membership level=”1,5,6,7,8,9,10,11,12″][membership]
